Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Hold rating on Biomarin Pharmaceutical but lowered its price target from $93 to $84.
October 30, 2024 | 5:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity has maintained a Hold rating on Biomarin Pharmaceutical and lowered its price target from $93 to $84, indicating a more cautious outlook.
The lowering of the price target from $93 to $84 by Canaccord Genuity suggests a less optimistic view on Biomarin's future performance, which could lead to a negative short-term impact on the stock price. The Hold rating indicates that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100